| Name | Title | Contact Details |
|---|---|---|
Donna Wren |
Associate General Counsel, Transactions | Profile |
Ilan Feuchtwang |
General Counsel | Profile |
Scott Bizily |
Associate General Counsel | Profile |
Stephanie Adamany |
Chief Legal Officer | Profile |
Proteus Biomedical is a Redwood City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
VitaKey`s technology platform provides for a wide range of advanced encapsulations triggered by desired pH levels or other stimuli. Our technology delivers targeted and time-controlled release of micronutrients, vitamins, probiotics, nutraceuticals, antioxidants, proteins and amino acids, and flavors, as well as excellent bioavailability.
EndGenitor Technologies is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC™) targeting EphA2; BT8009, a second-generation BTC targeting Nectin-4, a well-validated tumor antigen; and BT7480, a Bicycle TICA™ targeting Nectin-4 and agonizing CD137, in company-sponsored Phase I/II trials. In addition, BT1718, a BTC that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial sponsored by the Cancer Research UK Centre for Drug Development. Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Lexington, MA.
Jasper Therapeutics is a biotechnology company on a mission to make safer and potentially curative therapy possible for more patients in need. We are bringing together a team of biotech veterans, leading academic institutions and a strong syndicate of healthcare-focused investors to achieve our vision of developing new therapies for diseases of mast and stem cells, and safer and more effective conditioning for monogenetic diseases.